however, they differ in how they approach medications, personalization, and their care structures
This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway is trying to solve the problem
I don't over exercise anymore
These pathways are central to geroscience because dysregulated nutrient sensing, mitochondrial dysfunction, and inflammaging drive multiple age-related diseases
This is because discontinuing early can be viewed as non-adherence to the approved treatment plan